Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 19/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1968700 | 1.00 | CHRM3 (0.45) | CHRM3 | |
| SCHEMBL3230462 | 0.93 | CHRM3 (0.44) | CHRM3 | |
| SCHEMBL1966327 | 0.93 | CHRM3 (0.44) | CHRM3 | |
| SCHEMBL13458249 | 0.89 | CHRM3 (0.43) | CHRM3 | |
| SCHEMBL3229853 | 0.83 | HDAC1 (0.44) | CHRM3 | |
| SCHEMBL3229872 | 0.83 | HDAC1 (0.44) | CHRM3 | |
| SCHEMBL3226412 | 0.83 | BCL9 (0.39) | CHRM3 | |
| SCHEMBL9976632 | 0.80 | EGFR (0.43) | — | |
| SCHEMBL12356629 | 0.78 | NPC1 (0.45) | — | |
| SCHEMBL1965072 | 0.77 | TRPV1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202866-B2 | Ortho-aminoanilides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069328-A1 | NOVEL ORTHO-AMINOANILIDES FOR THE TREATMENT OF CANCER | IL4I1, MKI67, ABL1 | CHRM3 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.